Stock EOLS EVOLUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
12.75 USD -2.89% Intraday chart for Evolus, Inc. -4.14% +21.08%
05-07 Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-07 Transcript : Evolus, Inc., Q1 2024 Earnings Call, May 07, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (EOLS) EVOLUS Reports Q1 Revenue $59.3M, vs. Street Est of $57.3M
MT
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024
CI
AbbVie raises annual profit forecast on strong Skyrizi sales
RE
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau
CI
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours
MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M
MT
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024
CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals
RE
Evolus Reports Higher Q4, 2023 Preliminary Revenue, Expects 2024 Revenue to Rise as Much as 31%; Shares Climb
MT
Evolus, Inc. Announces Earnings Guidance for 2024
CI
Evolus Signs Licensing Deal With Symatese to Distribute Dermal Fillers in UK, Europe
MT
Evolus, Inc. Enters into Licensing Agreement with Symatese to Exclusively Distribute Next Generation Dermal Fillers in Europe
CI
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling
MT
US Consumer group seeks stronger warnings on Botox, similar treatments
RE
Evolus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (EOLS) EVOLUS Posts Q3 Revenue $50M, vs. Street Est of $44.4M
MT
Evolus, Inc. Raises Earnings Guidance for the Full Year 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. News Evolus, Inc.
  5. Highlights